Live
FierceBiotechPredicta links with Spanish university to offer diagnostic for blood cancersBioPharma DiveSummit pulls $500M share sale a day after announcing itEndpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysBioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekBioPharma DiveNovartis RNA drug acquired in $12B Avidity deal notches a trial winEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
BioWorld Nov 26, 2025

Samsung Life Public Welfare Foundation discovers new TLR signaling inhibitors

Samsung Life Public Welfare Foundation discovers new TLR signaling inhibitors

Original
Body unavailable. Use the original source.